Why the study?
Perioperative stroke rates remain high with aortic arch endografts despite technical advances, limiting their commercial availability.
Aortic arch endografting devices are currently under investigation in the US, but their commercial availability is limited by high rates of perioperative stroke.
Aortic arch endografting will undoubtedly expand in the population suitable for aortic arch repair. Currently, there are four endografts under investigation to treat aortic arch pathology including Gore's Thoracic Branch Endoprosthesis, Endospan's NEXUS Aortic Arch Stent Graft System, Terumo's RelayBranch Thoracic Stent-Graft System, and Cook's Zenith Arch Branched Graft. Despite advances in deployment technique, self-aligning features to mitigate aortic arch manipulation, and distal embolic protection, perioperative stroke continues to be high, limiting the devices from commercial availability. Here we discuss current devices under trial in the United States, limitations of aortic arch endografting, and future directions.
No takes yet. Share an insight, caveat, or question.
Glousman et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: